Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Eur J Cancer. 2022 Sep;172:130-137. doi: 10.1016/j.ejca.2022.05.027. Epub 2022 Jun 25.
Cigarette smoking represents the main risk factor for cancer development; however, less is known about the effects of active smoking on the outcome of cancer patients receiving systemic treatment, radiation therapy, or surgery.
A systematic review and meta-analysis were conducted searching the PubMed® and Web of Science® Library databases using specific Medical Subject Headings terms. Studies reporting on the prognostic impact of the smoking status concerning survival endpoints in cancer patients treated with systemic treatment, radiation therapy, or surgery were eligible for inclusion.
Of 1.380 articles reviewed, 12 reports including data from 31.785 patients with six different cancer types were considered eligible for inclusion. According to the meta-analysis of the overall effect, active smoking during cancer treatment was associated with an impaired overall survival (OS) and cancer-specific mortality (CSM) as compared to former or never smokers (OS: hazard ratio (HR) = 1.61, 95% CI: 1.19-2.17, p = 0.007; CSM: HR = 1.25, 95% CI: 1.01-1.54, p = 0.046). Moreover, smoking cessation led to a similar OS and CSM when comparing former to never smoking patients (OS: HR = 1.01, 95% CI: 0.87-1.18, p = 0.818; CSM: HR = 1.04, 95% CI: 0.91-1.20, p = 0.324).
These results underline active smoking during cancer treatment as an independent adverse prognostic factor, while smoking cessation can result in similar outcomes compared to never smokers. Limitations of the study were a substantial study heterogeneity concerning different cancer entities and variations of treatment modalities.
吸烟是癌症发展的主要危险因素;然而,对于接受系统治疗、放射治疗或手术的癌症患者,主动吸烟对其预后的影响知之甚少。
系统检索 PubMed® 和 Web of Science® Library 数据库,使用特定的医学主题词进行检索。纳入报告吸烟状况对接受系统治疗、放射治疗或手术治疗的癌症患者生存终点预后影响的研究。
在审查的 1380 篇文章中,有 12 篇报告包括来自 6 种不同癌症类型的 31785 名患者的数据,被认为符合纳入标准。根据总体效应的荟萃分析,与以前或从不吸烟的患者相比,癌症治疗期间的主动吸烟与总体生存(OS)和癌症特异性死亡率(CSM)受损相关(OS:风险比(HR)= 1.61,95%CI:1.19-2.17,p = 0.007;CSM:HR = 1.25,95%CI:1.01-1.54,p = 0.046)。此外,与从不吸烟的患者相比,戒烟后 OS 和 CSM 相似(OS:HR = 1.01,95%CI:0.87-1.18,p = 0.818;CSM:HR = 1.04,95%CI:0.91-1.20,p = 0.324)。
这些结果强调了癌症治疗期间的主动吸烟是一个独立的不良预后因素,而戒烟可以与从不吸烟的患者产生相似的结果。研究的局限性在于不同癌症实体和治疗方式的变化导致存在大量的研究异质性。